About Cocrystal Pharma

Developing and Commercializing Novel Small-Molecule Antiviral Drugs Using Proprietary Breakthrough Technologies

Cocrystal Pharma, Inc. is a pharmaceutical company with a mission to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Utilizing our unique nucleoside chemistry and Nobel Prize winning expertise, we create first- and best-in-class antiviral drugs. These technologies and our market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer.

Employing Nobel Prize Winning Expertise

Our award-winning team includes three industry leaders: Dr. Roger Kornberg (Founder and Chief Scientist), Raymond F. Schinazi (Founder and Chairman of our Board of Directors) and Phillip Frost (member of our Board of Directors).

Our Team

Teaming up with a Highly Successful Investment Group

Major investors include private investment firms, publicly traded healthcare/pharmaceutical companies and individuals.

View investor Group »

Partnerships & Licensing

The antiviral drug market and our technology are creating attractive partnership and M&A opportunities with pharmaceutical companies.

Become our Next Partner »


We are always looking for talented individuals to join our team.

View Careers »